MIGUEL REGUEIRO | SEBRADII 2021 | Galoá Proceedings

MIGUEL REGUEIRO

Is this your profile? Do login to access your certificates

Non-invasive predictors of maintaining remission in patients with moderately to severely active UC treated with tofacitinib who dose reduced from tofacitinib 10mg BID to 5mg BID: 6-month data from the double-blind, randomized RIVETING study
Geert D'Haens ¹
Marla Dubinski ²
Miguel Regueiro ³
Genoile Santana ⁴
Joana Torres ⁵
Nicole Kulisek ⁶
Sean Gardiner ⁶
Rajiv Mundayat ⁶
Jerome Paulissen ⁶
Nervin Lawendy ⁶
Chinyu Su ⁶
Irene Modesto ⁶
William Sandborn ⁷
¹ Amsterdam University Medical Centres, Amsterdam, The Netherlands
² Icahn School of Medicine at Mount Sinai
³ Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio, United States
⁴ Universidade do Estado da Bahia
⁵ Hospital Beatriz Ângelo, Loures, Portugal
⁶ Pfizer Inc.
⁷ University of California
Vol 2, 2021 -
139328

1. Medicina

Trabalho Original

Co-authors (12)